Actively Recruiting
A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Malignant Tumors
Led by Peking University First Hospital · Updated on 2024-11-07
350
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of 68Ga-P3 PET/CT imaging to detect prostate-specific membrane antigen (PSMA) expression in malignant tumors. PSMA is a protein found in high amounts on prostate cancer cells and blood vessels of tumors, making it an important target for imaging various cancers. This study aims to assess how well 68Ga-P3, a new PET imaging agent, works for diagnosing cancers that highly express PSMA. Participants with suspected or confirmed cancer will receive an intravenous injection of 68Ga-P3 at a dose of 0.06 to 0.08 mCi/kg. After the injection, PET imaging using 68Ga-P3 will be performed. Additionally, participants will undergo a whole-body 18F-FDG PET/CT scan within one week for comparison. This interventional study focuses on gathering diagnostic and detection information about malignant tumors. During the study, researchers will measure the diagnostic accuracy and detection capabilities of 68Ga-P3 PET/CT over one year. They will also evaluate the radiation dosage from 68Ga-P3, quantify its uptake, and correlate imaging results with pathological findings. Participants will be monitored through scans and tests as part of the imaging procedures, and the study will last for one year to collect these outcomes.
CONDITIONS
Brief Title
68Ga-P3 PET/CT Imaging in Malignancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed or suspected cancer
- Age between 18 and 75 years
- 18F-FDG PET/CT scan performed within 1 week prior to enrollment
- Signed written informed consent
You will not qualify if you...
- Pregnant or breastfeeding women
- Female patients planning to become pregnant within 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 week
Participants receive an intravenous injection of 68Ga-P3 followed by PET/CT imaging to evaluate PSMA expression in malignant tumors. They also undergo a whole-body 18F-FDG PET/CT scan within one week.
2 visits (in-person)
Duration - 1 year
Participants are monitored for diagnostic efficacy and safety outcomes over the course of 1 year following imaging procedures.
Visits as needed for follow-up assessments
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
X
Xing Yang, Dr.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here